JosephHabibi_MD Profile Banner
Joseph Sleiman, MD, FACP Profile
Joseph Sleiman, MD, FACP

@JosephHabibi_MD

Followers
5K
Following
13K
Media
1K
Statuses
5K

🏳️‍🌈🇱🇧 IBD fellow @ClevelandClinic, Alumni @PittGILiverNutr #SoMe Editor @ACG_EBGI ➡️ @AGA_CGH🧵 #CGH4ALL #IBDAlgorithm @MondayNightIBD👨‍⚕️ tweets my own

Cleveland, OH
Joined November 2012
Don't wanna be here? Send us removal request.
@JosephHabibi_MD
Joseph Sleiman, MD, FACP
10 days
Happy to bring back my USA education & GI experience in a full circle . 📣 Virtual Talk w/ Real-world advice:.-Residency & fellowship matching.-Research & leadership as an IMG.-Career-building in IM & GI. 🎯My journey from medical school in Lebanon to training & securing a
Tweet media one
0
13
77
@JosephHabibi_MD
Joseph Sleiman, MD, FACP
6 days
Tweet media one
0
5
9
@JosephHabibi_MD
Joseph Sleiman, MD, FACP
7 days
#CGH4ALL 📣.💊 GLP-1 agonists in IBD?.👀 Safe, effective for weight loss.🔥 May help reduce inflammation (↓ CRP).🌟 Especially promising in ulcerative colitis!. Read the complete study here @AGA_CGH . 🔗 Reported by @arianapg. @phillyIBDdoc @blakely_md
Tweet media one
1
8
30
@JosephHabibi_MD
Joseph Sleiman, MD, FACP
8 days
#CGH4ALL @AGA_CGH 📣. With rising prevalence of chronic liver disease in young adults, there is an increase in relevance for data on safety and outcomes for infertility treatment!. Reported by @Ansari_Zaid7. 🔗 @Meera_Garriga @MonikaSarkar @whcop
Tweet media one
0
7
10
@JosephHabibi_MD
Joseph Sleiman, MD, FACP
9 days
#CGH4ALL📣 💥.Injectable Naltrexone has an overall better GI and liver safety profile compared to other FDA-approved drugs for Alcohol use disorder (AUD) . @Wei_Zhang_Liver @doc_sooyoung. @AGA_CGH🔥!🔗 . Reported by @ifrahfatima. @BlaneyMD @NoureddinMD
Tweet media one
0
8
24
@JosephHabibi_MD
Joseph Sleiman, MD, FACP
11 days
RT @jalpa_devi: 😄 2 out of 2 abstracts accepted, excited to present at #ACG2025 in Phoenix🌵!.🧠 P1110: Global HCP Perspectives on AI in IBD….
0
4
0
@JosephHabibi_MD
Joseph Sleiman, MD, FACP
12 days
3rd @Y_ECCO_IBD Mentorship Forum, Vienna, Austria. ✅Becoming an IKL (Innovation knowledge Leader), not just a KOL.☑️Succeeding at living as a physician & scientist.✅Multi-center trial design simulation + shark tank.☑️New & old friends. @ibdseb @bverstockt @virgisolitano
Tweet media one
Tweet media two
Tweet media three
Tweet media four
0
4
30
@JosephHabibi_MD
Joseph Sleiman, MD, FACP
12 days
#CGH4ALL 📣.🧐How risky are subcentimeter liver nodules?.📊This systematic review shows up to 20% may develop HCC, but newer studies show lower risk.🎯Better risk stratification models are needed!. 🖇️ Reported by @arianapg. @KarimDahanMD @darinedaher
Tweet media one
0
0
10
@JosephHabibi_MD
Joseph Sleiman, MD, FACP
13 days
RT @SuhaAbushamma: 🗞️Check out the #REACHIBD summer newsletter for #GI fellows and early-career #IBD pros. Insightful patient stories, ☀️ #….
0
10
0
@JosephHabibi_MD
Joseph Sleiman, MD, FACP
13 days
RT @ign76: 🔵 Interested in Global IBD and future scenarios?. Very happy to see our review published in @UEGJournal with IBD Master and good….
0
20
0
@JosephHabibi_MD
Joseph Sleiman, MD, FACP
13 days
#CGH4ALL @AGA_CGH 📣. As we look for more targets in therapy of UC, this study reports on an IL-22 Agonist that did not have efficacy when compared to placebo or Vedo!. 🔗 Reported by @Ansari_Zaid7. @ibd_pal @EdBarnesMD @IBDGastroDocSg @Bealoquebea
Tweet media one
0
9
23
@JosephHabibi_MD
Joseph Sleiman, MD, FACP
14 days
#CGH4ALL @AGA_CGH 📣. It is inevitable that you will see patients with disorders of gut-brain interaction– read this expert review to learn about evaluation for coexisting hypermobility, orthostasis and mast cell disorders!. Reported by @Ansari_Zaid7. 🔗
Tweet media one
0
2
13
@JosephHabibi_MD
Joseph Sleiman, MD, FACP
15 days
#CGH4ALL📣 💥.🚨 New international consensus on ASUC trial design!.📖 #IBD #ASUC #UlcerativeColitis #ClinicalTrials #Gastroenterology. @AGA_CGH🔥!🔗 Reported by @ifrahfatima
Tweet media one
1
6
23
@JosephHabibi_MD
Joseph Sleiman, MD, FACP
16 days
#CGH4ALL 📣 @AGA_CGH.💊 Do antibiotics fuel early-onset colon cancer?.🧪 In this large US study, the answer is: not likely.📉 No clear link found between adult antibiotic use and EOCRC risk. 🖇️ Reported by @arianapg. @JeffLeeMD @aileenbui @kpnorcalGI
Tweet media one
1
3
14
@JosephHabibi_MD
Joseph Sleiman, MD, FACP
19 days
RT @AliSoroushMD: 🚨 Application deadline extended to July 18! . The ASGE AI Scholars Program offers a fully funded year of AI training for….
Tweet card summary image
aiforgi.org
Advance your career in gastroenterology with ASGE's AI Scholar Program—an innovative initiative training future leaders in artificial intelligence applications for GI care.
0
5
0
@JosephHabibi_MD
Joseph Sleiman, MD, FACP
20 days
RT @AGA_CGH: 📢 CGH is thrilled to welcome its new Editorial Fellows @slchung_md and @SedkiMD. 📰 To see the editorial fellows selected for….
0
1
0
@JosephHabibi_MD
Joseph Sleiman, MD, FACP
22 days
RT @AGA_CGH: Endoscopic Sedation Type During FLIP Panometry Does Not Significantly Impact FLIP Motility Classification Relative to Manometr….
0
3
0
@JosephHabibi_MD
Joseph Sleiman, MD, FACP
25 days
RT @clivejmiranda: ✨ My 1️⃣st year of GI fellowship was littered with pearls of wisdom. Here are a few of them:. 🕕 Ideally get it to 6 o’cl….
0
21
0
@JosephHabibi_MD
Joseph Sleiman, MD, FACP
26 days
#CGH4ALL 📣. #ImmuneCheckpointInhibitor–Induced Type 1 Diabetes.🔍 Rare but serious irAE - early recognition is key!. 📰 @AGA_CGH.🌐 Reported by @KAlsabb. @MaisamHaijaMD @VinayChandraMD @FergaGleeson @Vkumbhari @ChahalPrabhleen @DrJohnKisiel
Tweet media one
0
5
17
@JosephHabibi_MD
Joseph Sleiman, MD, FACP
27 days
#CGH4ALL.Which comorbidities😷 may impact the health-related quality of life🏃‍♂️in patients with alcohol related liver disease💉?. @AGA_CGH .🔗 @ebtapper @JasmohanBajaj @JonathanStineMD @AniKardashianMD @lilydaramd @KathleenCoreyMD @AdamMikMD @VivianOrtizMD
Tweet media one
0
4
10